{"entity":{"id":"nct03542175","kind":"trial","name":"Rucaparib with radiation after incomplete response to chemotherapy","aka":[],"tldr":"This completed study tested a DNA-repair drug with radiation after breast surgery. It does not offer new enrollment.","summary":"Registry status completed, last updated 2025-12-08. Enrollment is 31 actual. Residual non-metastatic TNBC or selected high-risk hormone-receptor-positive/HER2-negative disease after neoadjuvant chemotherapy and definitive surgery. Dose escalation studied rucaparib concurrently with radiotherapy and additional maintenance. The registry design is phase 1; completion is not evidence of adjuvant efficacy.","status":"completed","asOf":"2026-10-10","links":[{"label":"ClinicalTrials.gov NCT03542175","url":"https://clinicaltrials.gov/study/NCT03542175"}],"tags":[],"related":[],"cancers":["tnbc","breast-hr-positive"],"sections":[],"technologies":[],"targets":["parp"],"drugs":["rucaparib"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03542175","phase":"1","setting":"Residual non-metastatic TNBC or selected high-risk hormone-receptor-positive/HER2-negative disease after neoadjuvant chemotherapy and definitive surgery","sponsor":"Memorial Sloan Kettering Cancer Center","started":"2018-05-23","startedType":"actual","enrolled":31,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03542175/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"drug":[{"id":"rucaparib","kind":"drug","name":"Rucaparib","route":"/drugs/rucaparib/"}]}}